Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care

AIDS Patient Care and STDs

Volumn 24, Issue 4, 2010, Pages 223-227

  Wasserman, Peter ^a   Rubin, David S ^a  

^a NEW YORK HOSPITAL QUEENS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN D;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CROSS-SECTIONAL STUDY; HEALTH CARE PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; RECIPIENT; SMOKING; URBAN AREA; VIRUS LOAD; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

AGE FACTORS; CROSS-SECTIONAL STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEW YORK; PREVALENCE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SKIN PIGMENTATION; SMOKING; URBAN POPULATION; VITAMIN D DEFICIENCY;

EID: 77951262787     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2009.0241     Document Type: Article

References (34)

1. Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 148:680-684. (Pubitemid 351669113)
2. Cazanave C, Dupon M, Lavignolle-Aurillic V, et al. Reduced bone mineral density in HIV-infected patients: Prevalence and associated factors. AIDS 2008;22:395-402.
3. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficency virus (HIV)- infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499-3504.
4. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The longitudinal aging study Amsterdam. J Clin Endocrinol Metab 2003;88: 5766-5772. (Pubitemid 38033048)
5. Bischoff-Ferrari HA, Dietrich T, Orav EJ, et al. Higher 25- hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged -60y. Am J Clin Nutr 2004;80:752-758. (Pubitemid 41115542)
6. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25- Hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063-1069. (Pubitemid 351664326)
7. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Data from the Third National Health and Nutrition Survey. Arch Intern Med 2007;167:1159-1165.
8. Chiu KC, Chu A, Go VLW, Saad MF. Hypovitaminosis D is associated with insulin resistance and b cell dysfunction Am J Clin Nutr 2004;79:820-825. (Pubitemid 41103882)
9. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28. (Pubitemid 44699167)
10. Liu PT, Stenger S, Li H, et al. Toll-Like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;211:1770-1773.
11. Bolland MJ, Grey A, Horne AM, Thomas MG. Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: A case report. Ann Clin Microbiol Antimicrob 2008;7:3-7. (Pubitemid 351309033)
12. Hahn TJ, Hendin BA, Scharp CR, Haddad JG. Effects of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972;287:900-904.
13. Zhou C, Assem M, Tay JC, et al. Steroid and Xenobiotic receptor and vitamin D receptor crosstalk mediates CYP 24 expression and drug-induced osteomalacia J Clin Invest 2006;116:1703-1712. (Pubitemid 43911025)
14. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP 24 expression in drug-induced osteomalacia. J Clin Invest 2005;115:177-186. (Pubitemid 40385519)
15. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52:1663-1669. (Pubitemid 351614658)
16. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of buproprion in healthy subjects. J Acquir Immune Defic Syndr 2008;49:513-519.
17. Grant JP. Handbook of Total Parenteral Nutrition. Philadelphia: W.B. Saunders & Co., 1980.
18. National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES II). Centers for Disease Control and Prevention. United States Department of Health and Human Services.
19. Webb AR, Kline L, and Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-378.
20. Araujo AB, Travison TG, Esche GR, Holick MF, Chen TC, Mckinlay JB. Serum 25-hydroxyvitamin D and bone mineral density among Hispanic men. Osteoporosis Int. 2009;20:245-255.
21. Van Den Bout-Van Den Beukel CJP, Fievez L, Michels M, et al. Vitamin D deficiency among HIV Type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1-8.
22. Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS 2009;23:274-275.
23. Gyllensten K, Josephson F, Lidman K, et al. Severe deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 598N. AIDS 2006;20:1906-1907. (Pubitemid 44358915)
24. Bergshoeff AS, Fraaij PL, Ndagijimana J, et al. Increased dose of lopinavir=ritonavir compensates for efavirenzinduced drug-drug interaction in HIV-1 infected children. J Acquir Immune Defic Syndr 2005;39:63-68. (Pubitemid 40617020)
25. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-1023.
26. Wang H, Faucette SR, Gilbert D, et al. Glucocorticoid receptor enhancement of pregnane X receptor-mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 2003;31:620-630. (Pubitemid 36444171)
27. Yang X, Hashizume T, Shuhart MC, et al. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1a, 25- dihydroxyvitamin D3: Implications for drug-induced osteomalacia. Mol Pharmacol 2006;69:56-65. (Pubitemid 43048893)
28. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: Comparison with rifampin and Phenobarbital. J Clin Pharmacol 2004;44:1273-1281. (Pubitemid 39391486)
29. Watkins RE, Wisely GB, Moore LB, et al. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 2001;292:2329-2333.
30. Faucette SR, Zhang T-C, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320:72-80. (Pubitemid 46025721)
31. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-520. (Pubitemid 36293104)
32. Gupta RP, He YA, Patrick KS, Halpert JR, Bell NH. CYP3A4 Is a vitamin D-24- and 25-hydroxylase: Analysis of structure function by site-directed mutagenesis. J Clin Endo Metab 2005;90:1210-1219.
33. Staretz ME, Murphy SE, Patten CJ, et al. Comparative metabolism of the tobacco-related carcinogens benzo[A]- pyrene, 4- (methylnitrosamino)-1-(3- pyridyl)-1-butanone, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and N'- Nitrosonornicotine in human hepatic microsomes. Drug Metab Dispos 1997;25:154-162.
34. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162:2217-2222. (Pubitemid 35231591)